Global Favipiravir Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Favipiravir Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Favipiravir, sold under the brand name Avigan, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections. Like the experimental antiviral drugs (T-1105 and T-1106), it is a pyrazinecarboxamide derivative. It is being developed and manufactured by Toyama Chemical (Fujifilm group) and was approved for medical use in Japan in 2014. In 2016, Fujifilm licensend API for it to Zhejiang Hisun Pharmaceutical Co. of China. It became a generic drug in 2019.
Favipiravir report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Favipiravir market is projected to reach US$ 11 million in 2034, increasing from US$ 342.8 million in 2022, with the CAGR of -22.0% during the period of 2024 to 2034. Demand from Influenza Viruses and COVID-19 are the major drivers for the industry.
In the global Favipiravir market, ChemRar Group, Glenmark, Fujifilm, Dr. Reddy, R-Pharma are the key players. The global 5 Largest Favipiravir Players account for 70% market share by revenue. India hold a key market revenue share of the Favipiravir market which account for 73%. The classification of Favipiravir includes Brand Drug and Generic Drug. Brand Drug accounted for a share of 16% in the global Favipiravir market. Favipiravir is widely used for Influenza Viruses, COVID-19, etc. The most proportion of Favipiravir is used for COVID-19 and the proportion is 97%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Favipiravir market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Cipla
Lupin
Sun Pharma
Hisun Pharm
Segment by Type
Brand Drug
Generic Drug
Influenza Viruses
COVID-19
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Favipiravir market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Favipiravir, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Favipiravir industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Favipiravir in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Favipiravir introduction, etc. Favipiravir Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Favipiravir market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Favipiravir report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Favipiravir market is projected to reach US$ 11 million in 2034, increasing from US$ 342.8 million in 2022, with the CAGR of -22.0% during the period of 2024 to 2034. Demand from Influenza Viruses and COVID-19 are the major drivers for the industry.
In the global Favipiravir market, ChemRar Group, Glenmark, Fujifilm, Dr. Reddy, R-Pharma are the key players. The global 5 Largest Favipiravir Players account for 70% market share by revenue. India hold a key market revenue share of the Favipiravir market which account for 73%. The classification of Favipiravir includes Brand Drug and Generic Drug. Brand Drug accounted for a share of 16% in the global Favipiravir market. Favipiravir is widely used for Influenza Viruses, COVID-19, etc. The most proportion of Favipiravir is used for COVID-19 and the proportion is 97%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Favipiravir market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Cipla
Lupin
Sun Pharma
Hisun Pharm
Segment by Type
Brand Drug
Generic Drug
Segment by Application
Influenza Viruses
COVID-19
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Favipiravir market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Favipiravir, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Favipiravir industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Favipiravir in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Favipiravir introduction, etc. Favipiravir Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Favipiravir market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices